A new briefing from the UK Parliamentary Office of Science and Technology (POST) provides politicians with up-to-date information on the benefits and risks of psychedelic-assisted therapy, which brings into focus the arguments in favour and against reassessing Schedule 1 drugs.Written by Charles Bliss for Psychedelic Alpha.
